Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee.
about
Sensitivity of (18)F-FDG PET in evaluation of solitary pulmonary nodulesGlycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma.Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunitiesSocial differences in lung cancer management and survival in South East England: a cohort study.Clinicopathologic implication of ezrin expression in non-small cell lung cancer.Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkersVisceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.Glycoproteomics using fluid-based specimens in the discovery of lung cancer protein biomarkers: promise and challenge.Application of glycoproteomics for the discovery of biomarkers in lung cancer.⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer.[Novel morphological and molecular aspects of lung cancer].Predictive ability of the 2002 and 2010 versions of the Tumour-Node-Metastasis classification system regarding metastasis-free, cancer-specific and overall survival in a European renal cell carcinoma single-centre series.Comparison of the 2002 and 2010 TNM classification systems regarding outcome prediction in clear cell and papillary renal cell carcinoma.
P2860
Q28081859-6E1516E9-CB0A-4CB4-BBA3-B829B51C3B34Q30600084-D0C4AEC3-96D6-4095-BC49-5927A8EEFA93Q35996028-9AA6A0CA-16ED-4D11-87C9-18580C55438BQ36008023-48077C0F-C9C8-42C3-B48F-46F79B252F1FQ36374643-AF928F60-257F-457E-888B-10C1AC063C55Q36962487-B27AFF5E-A906-4A11-AAD8-B3C79860712DQ37280912-223F5F4A-2587-4D2B-A12F-48B7A1B5B946Q37365408-CA356625-3660-4288-8E7E-E0AD0AD8ACCBQ37660297-C5C811FD-3F80-4F71-83CD-706293EAA8E1Q37990397-6EAEDEC8-BE21-4090-A1B3-7110BC82DCA6Q43770251-0399CE9B-DAEE-4603-9304-5F54D7143ED8Q45264604-2255B104-C3B3-481E-BC8D-41ECE954A327Q53136892-846EAF9D-2A73-4757-9C70-1DA296C0B343Q53142785-14785ED9-5364-4346-A8F3-03549EBBAE44
P2860
Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@ast
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@en
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@nl
type
label
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@ast
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@en
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@nl
prefLabel
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@ast
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@en
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@nl
P1433
P1476
Reporting lung cancer patholog ...... f the IASLC Staging Committee.
@en
P2093
IASLC Staging Committee
William D Travis
P2860
P356
10.1111/J.1365-2559.2008.03179.X
P577
2009-01-01T00:00:00Z